Engineered immune cells take on deadly childhood brain cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Procurement Inclusion Criteria: * 1\) Diagnosis of GPC3-positive recurrent ATRT. * 2\) Age ≥ 6 months * 3\) Karnofsky/Lansky score ≥ 60% * 4\) Informed consent explained to, understood by, and signed by patient/guardian; copy provided * 5\) GPC3 expression by immunohistochemistry with extent score ≥ Grade 2 (\>25% positive tumor cells) and intensity score ≥ 2 (scale 0-4) Procurement Exclusion Criteria: * 1\) No history of organ transplantation * 2\) No known HIV positivity * 3\) No active bacterial, fungal, or viral infection (except Hepatitis B or Hepatitis C virus infections) * 4\) No other risk factors in which administration of the investigational agent is deemed not in the patient's best interest, in the opinion of the investigator Treatment Inclusion Criteria: * 1\) Age ≥ 6 months * 2\) Diagnosis of treatment refractory or unresectable ATRT after standard of care therapy * 3\) Lansky/Karnofsky score ≥ 60% * 4\) Stable neurologic exam for 7 days prior to enrollment * 5\) Stable or decreasing dose of steroids over past 7 days prior to surgery and administration of therapy (max allowable dose is 0.1mg/kg dexamethasone or equivalent per day) * 6\) Not receiving any concurrent anti-cancer therapy. * 7\) At least 6 weeks following craniospinal radiation therapy. * 8\) At least 14 days wash-out needed following small volume radiotherapy (i.e., Stereotactic Radiosurgery (SRS)). * 9\) At least 21 days or 5 half-lives (whichever is shorter) must have elapsed since any prior systemic therapy * 10\) Received any other forms of immunotherapy ≤ 42 days before administration of investigational agent * 11\) At least 28 days following bevacizumab * 12\) Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml/min * 13\) Total bilirubin \< 3 times ULN for age * 14\) INR ≤ 1.7 * 15\) Absolute neutrophil count \> 500/μl * 16\) Platelet count \> 100,000/μl (can be transfused but must be achieved prior to enrollment) * 17\) Hgb ≥ 7.0 g/dl (can be transfused) * 18\) Pulse oximetry \> 90% on room air * 19\) Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study * 20\) Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion. * 21\) Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent Treatment Exclusion Criteria: * 1\) Pregnancy or lactation (for women at child-bearing age, birth control is required) * 2\) Uncontrolled infection * 3\) Known HIV positivity * 4\) Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections) * 5\) History of organ transplantation